A long myth that how coconut oil lowers cholesterol and triglyceride and increases HDL levels is explained: Lauric acid-based therapy for Non-alcoholic fatty liver disease (NAFLD):Lauric acid (C12) or Dodecanoic acid, one of the main components of  coconut oil, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down-regulation of its target gene, 9/June/2018, 11.17 pm

Spread the love
        

The significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.

Research findings to Therapeutic opportunity:

This study suggests, for the first time, that coconut-derived compound Lauric acid (C12) or Dodecanoic acid may aid in the treatment of NAFLD. Lauric acid (C12) or Dodecanoic acid, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) increase HDL levels; (3) attenuate lipid deposition in the liver; and (4) inhibit progression to NAFLD (Fig. 1). Thus, pharmacological formulations encompassing “Lauric acid (C12) or Dodecanoic acid  or its analogs, either alone or in combination with other drugs,” may be used to treat NAFLD.

Figure 1. Mechanistic insights into how the coconut-derived compound Lauric acid (C12) or Dodecanoic acid decrease the expression of HMGCR. The coconut-derived compound Lauric acid (C12) or Dodecanoic acid  lowers cholesterol and triglyceride levels and increases HDL levels, through down-regulation of HMGCR
Figure 2. The chemical structure of Lauric acid (C12) or Dodecanoic acid. 

[easy_payment currency=”USD”]

Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by Dr. L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Lauric acid (C12) or Dodecanoic acid decrease the expression of HMGCR?

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation

References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., A long myth that how coconut oil lowers cholesterol and triglyceride and increases HDL levels is explained: Lauric acid-based therapy for Non-alcoholic fatty liver disease (NAFLD):Lauric acid (C12) or Dodecanoic acid, one of the main components of  coconut oil, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down-regulation of its target gene, 9/June/2018, 11.18 pm, Genome-2-Biomedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org


Spread the love